Akili creates global access platform for digital therapeutics, grants Shionogi license

Shionogi gained exclusive rights to develop and commercialize Akili's digital therapeutics for ADHD and autism spectrum disorder (ASD) in Japan and Taiwan.

Akili Interactive Labs Inc. (Boston, Mass.) will receive $20 million up front and is eligible for up to $105 million in development and commercial milestones, plus royalties. Shionogi & Co. Ltd. (Tokyo:4507) will help fund development costs and has committed to make an undisclosed equity investment in Akili, a PureTech Health plc (LSE:PRTC) company...